A Phase I/II, Open-Label, Dose-Escalation Study to Evaluate the Safety and Activity of Single Dose 90Y-Labeled IDEC-159, Humanized, Domain Deleted, Anti TAG-72 Monoclonal Antibody, in Subjects With Metastatic Colorectal Adenocarcinoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs IDEC 159 Y-90 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Aug 2010 Biomarkers information updated
- 15 Aug 2005 New trial record.